As of November 6, 2026, Dermata Therapeutics, Inc. is a publicly traded company (Nasdaq: DRMA). The largest holder reporting an active stake on Schedule 13D is Gerald Proehl, the executive officer and a director, at 17.3%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Kyri K. Van Hoose, the executive officer (9%) (Schedule 13D/A, February 23, 2026).
Is this your company?
About to sign with, pay or invest in Dermata Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Dermata Therapeutics, Inc. a real, registered company?
- Dermata Therapeutics, Inc. files with the SEC under CIK 1853816 (its SEC filings).
- Its shares are listed under the ticker DRMA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Dermata Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Bigger Michael (filed 2026-11-02).
Who are Dermata Therapeutics, Inc.'s owners and officers?
Dermata Therapeutics, Inc.: incorporated in Delaware; business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-11-02).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-01-07)
- : Executive Officer (Form D, 2026-01-07)
- : Executive Officer (Form D, 2026-01-07)
- : Executive Officer (Form D, 2026-01-07)
- : Director (Form D, 2026-01-07)
- : Director (Form D, 2026-01-07)
- : Director (Form D, 2026-01-07)
- : Director (Form D, 2026-01-07)
- : Director (Form D, 2026-01-07)
- : Director (Form D, 2026-01-07)
- : Director (Form D, 2026-01-07)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-02 | Bigger Michael | 8.36% |
| Schedule 13D, 2026-06-01 | Kyri K. Van Hoose | 9% |
| Schedule 13G/A, 2026-05-13 | Mitchell P. Kopin | 4.99% |
| Schedule 13G/A, 2026-04-22 | Bigger Capital Fund L P | 1.87% |
| Schedule 13D/A, 2026-02-23 | Proehl Gerald T | 17.3% |
| Schedule 13G/A, 2026-02-18 | Armistice Capital, LLC | 4.99% |
| Schedule 13G/A, 2026-02-17 | Armistice Capital, LLC | 4.99% |
| Schedule 13G/A, 2026-02-09 | Bigger Michael | 9.89% |
| Schedule 13D/A, 2026-02-02 | Proehl Gerald T | 19.6% |
| Schedule 13D/A, 2026-01-08 | Proehl Gerald T | 24.7% |
| Schedule 13G, 2026-01-02 | Mitchell P. Kopin | 5.5% |
| Schedule 13G, 2025-12-30 | Bigger Michael | 7.43% |
Questions about who owns Dermata Therapeutics, Inc.
Who owns Dermata Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Dermata Therapeutics, Inc.: Proehl Gerald T (17.3%, Schedule 13D/A, filed 2026-02-23), Kyri K. Van Hoose (9%, Schedule 13D, filed 2026-06-01) and Bigger Michael (8.36%, Schedule 13G, filed 2026-11-02).
Who are the largest shareholders of Dermata Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Dermata Therapeutics, Inc. on this page are Proehl Gerald T (17.3%), Kyri K. Van Hoose (9%) and Bigger Michael (8.36%).
When did Proehl Gerald T buy into Dermata Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Proehl Gerald T on this page is the Schedule 13D/A, filed 2026-01-08, reporting 24.7%; its latest, Schedule 13D/A filed 2026-02-23, reports 17.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Dermata Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Dermata Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dermata Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
22 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Dermata Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chairman and chief executive: 372,615 shares (9.3% of shares outstanding), 24 held directly and 372,591 indirectly (Form 4, 2026-08-18).
- , the chief financial officer and senior vice president: 232,463 shares (5.8% of shares outstanding) (Form 4, 2026-08-18).
- , a director: 196,946 shares (4.9% of shares outstanding) (Form 4, 2025-01-23).
- , a director: 81,469 shares (2.0% of shares outstanding), 314 held directly and 81,155 indirectly (Form 4, 2025-01-23).
- , the senior vice president and regulatory affairs: 1,046 shares (0.03% of shares outstanding), 1,012 held directly and 34 indirectly (Form 4, 2026-03-17).
Shares outstanding: 4,022,143 as of 2026-08-10, from the company's latest SEC cover page.
How much has Dermata Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-01-07 | $4.12M | $4.12M |
| Form D, 2025-01-28 | $2.55M | $2.55M |
| Form D, 2024-09-27 | $3.50M | $3.50M |
| Form D, 2023-06-12 | $0 | not stated |
Keep reading
More on Dermata Therapeutics, Inc. and the records around it.
Dermata Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Form D filing Jan 2026
Companies that share a holder
- BIGGER CAPITAL FUND L P also filed stake reports on 13 other companies: ClearPoint Neuro, Inc. (Nov 2026), BTC Digital Ltd. (Oct 2026), Neuraxis, INC (Aug 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/dermata-therapeutics